Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer

The emergence of immunotherapy has been an astounding breakthrough in cancer treatments. In particular, immune checkpoint inhibitors, targeting PD-1 and CTLA-4, have shown remarkable therapeutic outcomes. However, response rates from immunotherapy have been reported to be varied, with some having pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Law, Andrew M. K., Valdes-Mora, Fatima, Gallego-Ortega, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140518/
https://www.ncbi.nlm.nih.gov/pubmed/32121014
http://dx.doi.org/10.3390/cells9030561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140518/
https://www.ncbi.nlm.nih.gov/pubmed/32121014
http://dx.doi.org/10.3390/cells9030561

Ejemplares similares